James reaffirmed its Outperform rating and $175.00 price target for Natera (NASDAQ:NTRA), following updates to oncology guidelines that could impact the company's cancer testing product, Signatera.

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Synchrony Financial (SYF – Research Report) and ...